The Public-Comment Fight Over BPC-157, TB-500 and Five More Peptides Ahead of the July PCAC Vote

What Did the Partnership for Safe Medicines Tell the FDA?

With the 23–24 July PCAC hearing now days away, the public-comment record on docket FDA-2025-N-6895 has sharpened into two clearly opposed camps. In comments filed in July 2026, the patient-safety advocacy group Partnership for Safe Medicines (PSM) urged the Pharmacy Compounding Advisory Committee to reject adding any of the seven peptides under review — BPC-157, TB-500, KPV, MOTS-c, DSIP (emideltide), Semax and Epitalon — to the Section 503A Bulk Drug Substances Category 1 list.[1]

PSM's submission points to what it describes as a critical deficit in controlled human safety data, arguing that formally clearing these compounds for pharmacy compounding would effectively convert patients into uncontrolled, unmonitored research subjects — without the informed consent, dosing controls or adverse-event tracking that a genuine clinical trial requires. A companion post from the group lists five specific structural objections to adding any bulk peptide to the 503A list without an approved reference drug to compound from, including inconsistent raw-material sourcing and the difficulty regulators face verifying identity and purity at compounding-pharmacy scale.[2]

What Is the Compounding Industry's Counter-Argument?

On the other side of the docket sits the Alliance for Pharmacy Compounding (APC), a trade association representing licensed 503A compounding pharmacies. APC does not dispute that controlled human trial data for most of the seven peptides is thin. Its argument is a different one: that rejecting all seven outright does not remove demand, it simply pushes that demand toward the unregulated grey and black markets already supplying US consumers — a dynamic NPR reported on directly in its 8 July 2026 coverage of overseas peptide sellers filling the gap left by US compounding restrictions.[3]

In a recent post, APC proposed what it calls a “third way”: allowing licensed compounding pharmacists to prepare a narrower subset of these peptides under tight clinical oversight and USP 797 sterile-preparation standards, rather than the binary choice between a blanket ban and unrestricted approval that the PCAC vote technically presents. The post cites former US Surgeon General Jerome Adams, who has separately urged the FDA to pursue what he called “a structured, clinician-guided framework that brings existing demand under professional oversight while maintaining rigorous safety, quality, and research standards.”[4]

Where Does the FDA's Own Evidence Review Leave This Debate?

Both advocacy positions are responding to the same underlying evidence record. As covered in our earlier breakdown of the FDA's briefing documents, agency scientific staff posted their own review on 29 June 2026, reporting no identified human-administration studies for TB-500 or KPV and insufficient data to evaluate BPC-157 for its proposed uses. Neither PSM nor APC disputes that underlying finding — the disagreement is entirely about what policy conclusion should follow from it.

That is the structural tension the PCAC panel has to resolve on 23–24 July: the committee's own evidentiary starting point already favours caution, but its vote is advisory, and the FDA is not bound to follow it in either direction. A recommendation to reject would align with PSM's position and the agency's own reviewers; a recommendation to approve, or to approve a subset, would move toward APC's regulated middle ground.

What Happens at the Hearing and After?

The two-day hearing splits the seven peptides across separate sessions: BPC-157, KPV, TB-500 and MOTS-c are scheduled for 23 July, with DSIP (emideltide), Semax and Epitalon taking 24 July — each considered in both free-base and acetate-salt form. Public comments, FDA briefing documents, and now the competing PSM and APC submissions all form part of the record the committee members will have in front of them when they vote.[5]

A PCAC recommendation, whichever way it goes, is not the end of the process. The committee's vote is advisory; the FDA reviews it and separately decides whether to initiate formal rulemaking to add any of the seven to the 503A Category 1 list. Even a unanimous vote to approve would not make compounding legal immediately — that requires a subsequent FDA rulemaking step with its own timeline.

What Should UK Researchers Take From This?

The 503A Bulk Drug Substances List and the PCAC advisory process are US-specific mechanisms with no legal force in the UK. Neither PSM's opposition nor APC's proposed “third way” changes the regulatory status of BPC-157, TB-500, KPV, MOTS-c, Semax or DSIP as research reagents under UK law, which is governed separately by the Human Medicines Regulations 2012 and MHRA guidance — see our guide on whether research peptides are legal in the UK.

What both sides of this debate agree on, even while disagreeing on policy, is that the published human evidence base for several of these seven compounds is thin or absent. That is precisely why Velox Peptides supplies BPC-157, TB-500, KPV, MOTS-c, Semax and DSIP strictly as HPLC-verified in vitro research reagents, with batch-specific certificates of analysis, and makes no therapeutic or health claims for any of them.

These compounds are supplied as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA for use in our products. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.

Frequently Asked Questions